Fig. 2: Efficacy of canakinumab in lower-risk MDS patients. | Nature Communications

Fig. 2: Efficacy of canakinumab in lower-risk MDS patients.

From: The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial

Fig. 2

A Swimmer’s plot showing transfusions, treatment durations, and responses of MDS patients enrolled in the canakinumab trial (n = 25). Red dots represent independent evaluations of transfusion needs in each patient; the dotted square represents the GI bleeding time in patient UPN-04. GI, gastrointestinal; black lines represent the duration of response. HI-E, hematological improvement-erythroid; HI-P, hematological improvement-platelets; SD, stable disease; PD, progressive disease. B Kaplan–Meier survival estimate curves for overall survival (left) and progression-free survival (right) stratified by HMA therapy status. C Kaplan–Meier survival estimate curves for overall survival (left) and progression-free survival (right) stratified by IPSS-M risk. Source data are provided as a Source Data file.

Back to article page